Open AccessManagement of multiple myeloma patients with renal disease
Author(s) -
Camelia ACHIM,
Eliza SIMSENSOHN,
Sorina BADELITA,
Anca ZGURA,
Bogdan HAINEALA
Publication year - 2021
Publication title -
romanian journal of medical practice
Language(s) - English
Resource type - Journals
eISSN - 2069-6108
pISSN - 1842-8258
DOI - 10.37897/rjmp.2021.4.3
Subject(s) - plasma cell dyscrasia , multiple myeloma , dyscrasia , medicine , complication , incidence (geometry) , disease , nephropathy , mortality rate , gastroenterology , kidney disease , plasma cell , intensive care medicine , immunology , immunoglobulin light chain , endocrinology , physics , antibody , optics , diabetes mellitus
Multiple myeloma (MM) is a plasma cell dyscrasia, accounting for 10% of all hematological malignancies, which translates into a global age-standardized incidence and mortality rate of 2:1 per 100.000 and 1.39 per 100.000 respectively (1). Kidney disease is a very common complication of MM, increasing the mortality and being a poor prognostic factor. Renal impairment is often the first reason for patient admission, leading to the plasma cell dyscrasia as being the cause. 40% of patients with cast nephropathy had previously undiagnosed myeloma (2).The aim of this paper is to show that Prompt diagnosis and initiation of therapy warrants better patient survival and delays, or even prevents organ damage in multiple myeloma.